High-density lipoproteins and cerebrovascular integrity in Alzheimer's disease

Cell Metabolism

Volumn 19, Issue 4, 2014, Pages 574-591

  Stukas, Sophie ^a   Robert, Jérôme ^a   Wellington, Cheryl L ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID; HIGH DENSITY LIPOPROTEIN; AMYLOID BETA PROTEIN; GLUCOSE;

ALZHEIMER DISEASE; BLOOD BRAIN BARRIER; BLOOD VESSEL TONE; BRAIN BLOOD FLOW; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; COMORBIDITY; DIABETES MELLITUS; DYSLIPIDEMIA; ENDOTHELIUM CELL; GLUCOSE METABOLISM; HUMAN; HYPERTENSION; INFLAMMATION; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW; RISK FACTOR; VASODILATATION; BIOLOGICAL MODEL; BLOOD; BLOOD FLOW; CENTRAL NERVOUS SYSTEM; COMPLICATION; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; VASCULAR SMOOTH MUSCLE; VASCULARIZATION;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; CENTRAL NERVOUS SYSTEM; CEREBROVASCULAR DISORDERS; GLUCOSE; HUMANS; LIPOPROTEINS, HDL; MODELS, BIOLOGICAL; MUSCLE, SMOOTH, VASCULAR; REGIONAL BLOOD FLOW; RISK FACTORS;

EID: 84897547991     PISSN: 15504131     EISSN: 19327420     Source Type: Journal    
DOI: 10.1016/j.cmet.2014.01.003     Document Type: Review

References (264)

1. S. Abe-Dohmae, Y. Ikeda, M. Matsuo, M. Hayashi, K. Okuhira, K. Ueda, and S. Yokoyama Human ABCA7 supports apolipoprotein-mediated release of cellular cholesterol and phospholipid to generate high density lipoprotein J. Biol. Chem. 279 2004 604 611
2. V. Adams, C. Besler, T. Fischer, M. Riwanto, F. Noack, R. Hollriegel, A. Oberbach, N. Jehmlich, U. Volker, and E.B. Winzer et al. Exercise training in patients with chronic heart failure promotes restoration of high-density lipoprotein functional properties Circ. Res. 113 2013 1345 1355
3. J. Attems, K. Jellinger, D.R. Thal, and W. Van Nostrand Review: sporadic cerebral amyloid angiopathy Neuropathol. Appl. Neurobiol. 37 2011 75 93
4. B.J. Bacskai, M.P. Frosch, S.H. Freeman, S.B. Raymond, J.C. Augustinack, K.A. Johnson, M.C. Irizarry, W.E. Klunk, C.A. Mathis, and S.T. Dekosky et al. Molecular imaging with Pittsburgh Compound B confirmed at autopsy: a case report Arch. Neurol. 64 2007 431 434
5. D. Bailey, R. Jahagirdar, A. Gordon, A. Hafiane, S. Campbell, S. Chatur, G.S. Wagner, H.C. Hansen, F.S. Chiacchia, and J. Johansson et al. RVX-208: a small molecule that increases apolipoprotein A-I and high-density lipoprotein cholesterol in vitro and in vivo J. Am. Coll. Cardiol. 55 2010 2580 2589
6. E. Barbero-Camps, A. Fernández, L. Martínez, J.C. Fernández-Checa, and A. Colell APP/PS1 mice overexpressing SREBP-2 exhibit combined Aβ accumulation and tau pathology underlying Alzheimer's disease Hum. Mol. Genet. 22 2013 3460 3476
7. P.J. Barter, M. Caulfield, M. Eriksson, S.M. Grundy, J.J. Kastelein, M. Komajda, J. Lopez-Sendon, L. Mosca, J.C. Tardif, D.D. Waters ILLUMINATE Investigators Effects of torcetrapib in patients at high risk for coronary events N. Engl. J. Med. 357 2007 2109 2122
8. R.D. Bell, A.P. Sagare, A.E. Friedman, G.S. Bedi, D.M. Holtzman, R. Deane, and B.V. Zlokovic Transport pathways for clearance of human Alzheimer's amyloid beta-peptide and apolipoproteins E and J in the mouse central nervous system J. Cereb. Blood Flow Metab. 27 2007 909 918
9. R.D. Bell, R. Deane, N. Chow, X. Long, A. Sagare, I. Singh, J.W. Streb, H. Guo, A. Rubio, and W. Van Nostrand et al. SRF and myocardin regulate LRP-mediated amyloid-beta clearance in brain vascular cells Nat. Cell Biol. 11 2009 143 153
10. R.D. Bell, E.A. Winkler, I. Singh, A.P. Sagare, R. Deane, Z. Wu, D.M. Holtzman, C. Betsholtz, A. Armulik, and J. Sallstrom et al. Apolipoprotein E controls cerebrovascular integrity via cyclophilin A Nature 485 2012 512 516
11. C. Besler, K. Heinrich, L. Rohrer, C. Doerries, M. Riwanto, D.M. Shih, A. Chroni, K. Yonekawa, S. Stein, and N. Schaefer et al. Mechanisms underlying adverse effects of HDL on eNOS-activating pathways in patients with coronary artery disease J. Clin. Invest. 121 2011 2693 2708
12. A. Blazek, J. Rutsky, K. Osei, A. Maiseyeu, and S. Rajagopalan Exercise-mediated changes in high-density lipoprotein: impact on form and function Am. Heart J. 166 2013 392 400
13. M. Bonarek, P. Barberger-Gateau, L. Letenneur, V. Deschamps, A. Iron, B. Dubroca, and J.F. Dartigues Relationships between cholesterol, apolipoprotein E polymorphism and dementia: a cross-sectional analysis from the PAQUID study Neuroepidemiology 19 2000 141 148
14. S.Y. Bookheimer, M.H. Strojwas, M.S. Cohen, A.M. Saunders, M.A. Pericak-Vance, J.C. Mazziotta, and G.W. Small Patterns of brain activation in people at risk for Alzheimer's disease N. Engl. J. Med. 343 2000 450 456
15. I. Borghini, F. Barja, D. Pometta, and R.W. James Characterization of subpopulations of lipoprotein particles isolated from human cerebrospinal fluid Biochim. Biophys. Acta 1255 1995 192 200
16. S.A. Brown, K. Schmitt, and A. Eckert Aging and circadian disruption: causes and effects Aging (Albany, N.Y. Online) 3 2011 813 817
17. L.R. Brunham, J.K. Kruit, J. Iqbal, C. Fievet, J.M. Timmins, T.D. Pape, B.A. Coburn, N. Bissada, B. Staels, and A.K. Groen et al. Intestinal ABCA1 directly contributes to HDL biogenesis in vivo J. Clin. Invest. 116 2006 1052 1062
18. F. Cacciatore, P. Abete, N. Ferrara, G. Paolisso, L. Amato, S. Canonico, S. Maggi, M. Varricchio, F. Rengo Osservatorio Geriatrico Campano Group The role of blood pressure in cognitive impairment in an elderly population J. Hypertens. 15 1997 135 142
19. L. Calabresi, G. Franceschini, C.R. Sirtori, A. De Palma, M. Saresella, P. Ferrante, and D. Taramelli Inhibition of VCAM-1 expression in endothelial cells by reconstituted high density lipoproteins Biochem. Biophys. Res. Commun. 238 1997 61 65
20. L. Camont, M.J. Chapman, and A. Kontush Biological activities of HDL subpopulations and their relevance to cardiovascular disease Trends Mol. Med. 17 2011 594 603
21. A. Carrano, J.J. Hoozemans, S.M. van der Vies, A.J. Rozemuller, J. van Horssen, and H.E. de Vries Amyloid Beta induces oxidative stress-mediated blood-brain barrier changes in capillary amyloid angiopathy Antioxid. Redox Signal. 15 2011 1167 1178
22. A. Casella-Filho, A.C. Chagas, R.C. Maranhão, I.C. Trombetta, F.H. Cesena, V.M. Silva, J.E. Tanus-Santos, C.E. Negrão, and P.L. da Luz Effect of exercise training on plasma levels and functional properties of high-density lipoprotein cholesterol in the metabolic syndrome Am. J. Cardiol. 107 2011 1168 1172
23. E.M. Castaño, A.E. Roher, C.L. Esh, T.A. Kokjohn, and T. Beach Comparative proteomics of cerebrospinal fluid in neuropathologically-confirmed Alzheimer's disease and non-demented elderly subjects Neurol. Res. 28 2006 155 163
24. J.M. Castellano, J. Kim, F.R. Stewart, H. Jiang, R.B. DeMattos, B.W. Patterson, A.M. Fagan, J.C. Morris, K.G. Mawuenyega, and C. Cruchaga et al. Human apoE isoforms differentially regulate brain amyloid-β peptide clearance Sci. Transl. Med. 3 2011 89ra57
25. C. Cavelier, L. Rohrer, and A. von Eckardstein ATP-Binding cassette transporter A1 modulates apolipoprotein A-I transcytosis through aortic endothelial cells Circ. Res. 99 2006 1060 1066
26. C. Cavelier, P.M. Ohnsorg, L. Rohrer, and A. von Eckardstein The β-chain of cell surface F(0)F(1) ATPase modulates apoA-I and HDL transcytosis through aortic endothelial cells Arterioscler. Thromb. Vasc. Biol. 32 2012 131 139
27. K. Chalmers, G.K. Wilcock, and S. Love APOE epsilon 4 influences the pathological phenotype of Alzheimer's disease by favouring cerebrovascular over parenchymal accumulation of A beta protein Neuropathol. Appl. Neurobiol. 29 2003 231 238
28. S.L. Chan, W.S. Kim, J.B. Kwok, A.F. Hill, R. Cappai, K.A. Rye, and B. Garner ATP-binding cassette transporter A7 regulates processing of amyloid precursor protein in vitro J. Neurochem. 106 2008 793 804
29. H. Chiba, H. Akita, S.P. Hui, Y. Takahashi, H. Nagasaka, H. Fuda, and K. Kobayashi Effects of triamcinolone on brain and cerebrospinal fluid apolipoprotein E levels in rats Life Sci. 60 1997 1757 1761
30. G.W. Cockerill, K.A. Rye, J.R. Gamble, M.A. Vadas, and P.J. Barter High-density lipoproteins inhibit cytokine-induced expression of endothelial cell adhesion molecules Arterioscler. Thromb. Vasc. Biol. 15 1995 1987 1994
31. P.E. Cramer, J.R. Cirrito, D.W. Wesson, C.Y. Lee, J.C. Karlo, A.E. Zinn, B.T. Casali, J.L. Restivo, W.D. Goebel, and M.J. James et al. ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models Science 335 2012 1503 1506
32. R.F. de Bruijn, E.M. Schrijvers, K.A. de Groot, J.C. Witteman, A. Hofman, O.H. Franco, P.J. Koudstaal, and M.A. Ikram The association between physical activity and dementia in an elderly population: the Rotterdam Study Eur. J. Epidemiol. 28 2013 277 283
33. J.C. de la Torre Critical threshold cerebral hypoperfusion causes Alzheimer's disease? Acta Neuropathol. 98 1999 1 8
34. J.C. de la Torre Cerebral hemodynamics and vascular risk factors: setting the stage for Alzheimer's disease J. Alzheimers Dis. 32 2012 553 567
35. J. de Vries-van der Weij, W. de Haan, L. Hu, M. Kuif, H.L. Oei, J.W. van der Hoorn, L.M. Havekes, H.M. Princen, J.A. Romijn, J.W. Smit, and P.C. Rensen Bexarotene induces dyslipidemia by increased very low-density lipoprotein production and cholesteryl ester transfer protein-mediated reduction of high-density lipoprotein Endocrinology 150 2009 2368 2375
36. R. Deane, A. Sagare, K. Hamm, M. Parisi, S. Lane, M.B. Finn, D.M. Holtzman, and B.V. Zlokovic apoE isoform-specific disruption of amyloid beta peptide clearance from mouse brain J. Clin. Invest. 118 2008 4002 4013
37. S.P. Deeny, D. Poeppel, J.B. Zimmerman, S.M. Roth, J. Brandauer, S. Witkowski, J.W. Hearn, A.T. Ludlow, J.L. Contreras-Vidal, J. Brandt, and B.D. Hatfield Exercise, APOE, and working memory: MEG and behavioral evidence for benefit of exercise in epsilon4 carriers Biol. Psychol. 78 2008 179 187
38. L.F. Defina, B.L. Willis, N.B. Radford, A. Gao, D. Leonard, W.L. Haskell, M.F. Weiner, and J.D. Berry The association between midlife cardiorespiratory fitness levels and later-life dementia: a cohort study Ann. Intern. Med. 158 2013 162 168
39. R.B. DeMattos, R.P. Brendza, J.E. Heuser, M. Kierson, J.R. Cirrito, J. Fryer, P.M. Sullivan, A.M. Fagan, X. Han, and D.M. Holtzman Purification and characterization of astrocyte-secreted apolipoprotein E and J-containing lipoproteins from wild-type and human apoE transgenic mice Neurochem. Int. 39 2001 415 425
40. N. Demeester, G. Castro, C. Desrumaux, C. De Geitere, J.C. Fruchart, P. Santens, E. Mulleners, S. Engelborghs, P.P. De Deyn, and J. Vandekerckhove et al. Characterization and functional studies of lipoproteins, lipid transfer proteins, and lecithin:cholesterol acyltransferase in CSF of normal individuals and patients with Alzheimer's disease J. Lipid Res. 41 2000 963 974
41. N.A. Dennis, J.N. Browndyke, J. Stokes, A. Need, J.R. Burke, K.A. Welsh-Bohmer, and R. Cabeza Temporal lobe functional activity and connectivity in young adult APOE varepsilon4 carriers Alzheimers Dement. 6 2010 303 311
42. E. Di Angelantonio, N. Sarwar, P. Perry, S. Kaptoge, K.K. Ray, A. Thompson, A.M. Wood, S. Lewington, N. Sattar, C.J. Packard Emerging Risk Factors Collaboration Major lipids, apolipoproteins, and risk of vascular disease JAMA 302 2009 1993 2000
43. S. Diditchenko, A. Gille, I. Pragst, D. Stadler, M. Waelchli, R. Hamilton, A. Leis, and S.D. Wright Novel formulation of a reconstituted high-density lipoprotein (CSL112) dramatically enhances ABCA1-dependent cholesterol efflux Arterioscler. Thromb. Vasc. Biol. 33 2013 2202 2211
44. P. Dimayuga, J. Zhu, S. Oguchi, K.Y. Chyu, X.O. Xu, J. Yano, P.K. Shah, J. Nilsson, and B. Cercek Reconstituted HDL containing human apolipoprotein A-1 reduces VCAM-1 expression and neointima formation following periadventitial cuff-induced carotid injury in apoE null mice Biochem. Biophys. Res. Commun. 264 1999 465 468
45. J.C. Dodart, R.A. Marr, M. Koistinaho, B.M. Gregersen, S. Malkani, I.M. Verma, and S.M. Paul Gene delivery of human apolipoprotein E alters brain Abeta burden in a mouse model of Alzheimer's disease Proc. Natl. Acad. Sci. USA 102 2005 1211 1216
46. J.J. Donkin, S. Stukas, V. Hirsch-Reinshagen, D. Namjoshi, A. Wilkinson, S. May, J. Chan, J. Fan, J. Collins, and C.L. Wellington ATP-binding cassette transporter A1 mediates the beneficial effects of the liver X receptor agonist GW3965 on object recognition memory and amyloid burden in amyloid precursor protein/presenilin 1 mice J. Biol. Chem. 285 2010 34144 34154
47. A. Drzezga, T. Grimmer, G. Henriksen, M. Mühlau, R. Perneczky, I. Miederer, C. Praus, C. Sorg, A. Wohlschläger, and M. Riemenschneider et al. Effect of APOE genotype on amyloid plaque load and gray matter volume in Alzheimer disease Neurology 72 2009 1487 1494
48. E. Duron, and O. Hanon Vascular risk factors, cognitive decline, and dementia Vasc. Health Risk Manag. 4 2008 363 381
49. J.L. Durstine, P.W. Grandjean, P.G. Davis, M.A. Ferguson, N.L. Alderson, and K.D. DuBose Blood lipid and lipoprotein adaptations to exercise: a quantitative analysis Sports Med. 31 2001 1033 1062
50. R. Easton, A. Gille, D. D'Andrea, R. Davis, S.D. Wright, and C. Shear A multiple ascending dose study of CSL112, an infused formulation of ApoA-I J. Clin. Pharmacol. 2013
51. M.F. Elias, M.A. Robbins, M.M. Budge, W.P. Abhayaratna, G.A. Dore, and P.K. Elias Arterial pulse wave velocity and cognition with advancing age Hypertension 53 2009 668 673
52. E.C. Eringa, E.H. Serne, R.I. Meijer, C.G. Schalkwijk, A.J. Houben, C.D. Stehouwer, Y.M. Smulders, and V.W. van Hinsbergh Endothelial dysfunction in (pre)diabetes: characteristics, causative mechanisms and pathogenic role in type 2 diabetes Rev. Endocr. Metab. Disord. 14 2013 39 48
53. J.L. Etnier, R.J. Caselli, E.M. Reiman, G.E. Alexander, B.A. Sibley, D. Tessier, and E.C. McLemore Cognitive performance in older women relative to ApoE-epsilon4 genotype and aerobic fitness Med. Sci. Sports Exerc. 39 2007 199 207
54. A.M. Fagan, D.M. Holtzman, G. Munson, T. Mathur, D. Schneider, L.K. Chang, G.S. Getz, C.A. Reardon, J. Lukens, J.A. Shah, and M.J. LaDu Unique lipoproteins secreted by primary astrocytes from wild type, apoE (-/-), and human apoE transgenic mice J. Biol. Chem. 274 1999 30001 30007
55. G. Faraco, and C. Iadecola Hypertension: a harbinger of stroke and dementia Hypertension 62 2013 810 817
56. A.J. Farrall, and J.M. Wardlaw Blood-brain barrier: ageing and microvascular disease - systematic review and meta-analysis Neurobiol. Aging 30 2009 337 352
57. M. Fiala, L. Zhang, X. Gan, B. Sherry, D. Taub, M.C. Graves, S. Hama, D. Way, M. Weinand, and M. Witte et al. Amyloid-beta induces chemokine secretion and monocyte migration across a human blood - brain barrier model Mol. Med. 4 1998 480 489
58. N. Filippini, B.J. MacIntosh, M.G. Hough, G.M. Goodwin, G.B. Frisoni, S.M. Smith, P.M. Matthews, C.F. Beckmann, and C.E. Mackay Distinct patterns of brain activity in young carriers of the APOE-epsilon4 allele Proc. Natl. Acad. Sci. USA 106 2009 7209 7214
59. N. Filippini, K.P. Ebmeier, B.J. MacIntosh, A.J. Trachtenberg, G.B. Frisoni, G.K. Wilcock, C.F. Beckmann, S.M. Smith, P.M. Matthews, and C.E. Mackay Differential effects of the APOE genotype on brain function across the lifespan Neuroimage 54 2011 602 610
60. J. Fioravanti, J. Medina-Echeverz, N. Ardaiz, C. Gomar, Z.P. Parra-Guillén, J. Prieto, and P. Berraondo The fusion protein of IFN-α and apolipoprotein A-I crosses the blood-brain barrier by a saturable transport mechanism J. Immunol. 188 2012 3988 3992
61. N.F. Fitz, A.A. Cronican, I. Lefterov, and R. Koldamova Comment on "ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models" Science 340 2013 924-c
62. A.S. Fleisher, K. Chen, X. Liu, N. Ayutyanont, A. Roontiva, P. Thiyyagura, H. Protas, A.D. Joshi, M. Sabbagh, and C.H. Sadowsky et al. Apolipoprotein E ε4 and age effects on florbetapir positron emission tomography in healthy aging and Alzheimer disease Neurobiol. Aging 34 2013 1 12
63. J.D. Fryer, K. Simmons, M. Parsadanian, K.R. Bales, S.M. Paul, P.M. Sullivan, and D.M. Holtzman Human apolipoprotein E4 alters the amyloid-beta 40:42 ratio and promotes the formation of cerebral amyloid angiopathy in an amyloid precursor protein transgenic model J. Neurosci. 25 2005 2803 2810
64. R. Fukuyama, T. Mizuno, S. Mori, K. Yanagisawa, K. Nakajima, and S. Fushiki Age-dependent decline in the apolipoprotein E level in cerebrospinal fluid from control subjects and its increase in cerebrospinal fluid from patients with Alzheimer's disease Eur. Neurol. 43 2000 161 169
65. R. Giri, Y. Shen, M. Stins, S. Du Yan, A.M. Schmidt, D. Stern, K.S. Kim, B. Zlokovic, and V.K. Kalra beta-amyloid-induced migration of monocytes across human brain endothelial cells involves RAGE and PECAM-1 Am. J. Physiol. Cell Physiol. 279 2000 C1772 C1781
66. R. Giri, S. Selvaraj, C.A. Miller, F. Hofman, S.D. Yan, D. Stern, B.V. Zlokovic, and V.K. Kalra Effect of endothelial cell polarity on beta-amyloid-induced migration of monocytes across normal and AD endothelium Am. J. Physiol. Cell Physiol. 283 2002 C895 C904
67. L. Glodzik, H. Rusinek, E. Pirraglia, P. McHugh, W. Tsui, S. Williams, M. Cummings, Y. Li, K. Rich, and C. Randall et al. Blood pressure decrease correlates with tau pathology and memory decline in hypertensive elderly Neurobiol. Aging 35 2014 64 71
68. F.C. Goldstein, A.I. Levey, and N.K. Steenland High blood pressure and cognitive decline in mild cognitive impairment J. Am. Geriatr. Soc. 61 2013 67 73
69. M. Gomaraschi, A. Ossoli, E. Favari, M.P. Adorni, G. Sinagra, L. Cattin, F. Veglia, F. Bernini, G. Franceschini, and L. Calabresi Inflammation impairs eNOS activation by HDL in patients with acute coronary syndrome Cardiovasc. Res. 100 2013 36 43
70. F.J. Gonzalez-Velasquez, J.A. Kotarek, and M.A. Moss Soluble aggregates of the amyloid-beta protein selectively stimulate permeability in human brain microvascular endothelial monolayers J. Neurochem. 107 2008 466 477
71. P. Grammas Neurovascular dysfunction, inflammation and endothelial activation: implications for the pathogenesis of Alzheimer's disease J. Neuroinflammation 8 2011 26
72. A. Grefhorst, B.M. Elzinga, P.J. Voshol, T. Plösch, T. Kok, V.W. Bloks, F.H. van der Sluijs, L.M. Havekes, J.A. Romijn, H.J. Verkade, and F. Kuipers Stimulation of lipogenesis by pharmacological activation of the liver X receptor leads to production of large, triglyceride-rich very low density lipoprotein particles J. Biol. Chem. 277 2002 34182 34190
73. H.T.C. Group HPS2-THRIVE Collaborative Group HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment Eur. Heart J. 34 2013 1279 1291
74. J.R. Guyton, S.E. Miller, M.E. Martin, W.A. Khan, A.D. Roses, and W.J. Strittmatter Novel large apolipoprotein E-containing lipoproteins of density 1.006-1.060 g/ml in human cerebrospinal fluid J. Neurochem. 70 1998 1235 1240
75. A. Hafezi-Moghadam, K.L. Thomas, and D.D. Wagner ApoE deficiency leads to a progressive age-dependent blood-brain barrier leakage Am. J. Physiol. Cell Physiol. 292 2007 C1256 C1262
76. O. Hanon, S. Haulon, H. Lenoir, M.L. Seux, A.S. Rigaud, M. Safar, X. Girerd, and F. Forette Relationship between arterial stiffness and cognitive function in elderly subjects with complaints of memory loss Stroke 36 2005 2193 2197
77. H. Hanyu, T. Sato, K. Hirao, H. Kanetaka, T. Iwamoto, and K. Koizumi The progression of cognitive deterioration and regional cerebral blood flow patterns in Alzheimer's disease: a longitudinal SPECT study J. Neurol. Sci. 290 2010 96 101
78. S.D. Harr, L. Uint, R. Hollister, B.T. Hyman, and A.J. Mendez Brain expression of apolipoproteins E, J, and A-I in Alzheimer's disease J. Neurochem. 66 1996 2429 2435
79. A.M. Hartz, B. Bauer, E.L. Soldner, A. Wolf, S. Boy, R. Backhaus, I. Mihaljevic, U. Bogdahn, H.H. Klünemann, G. Schuierer, and F. Schlachetzki Amyloid-β contributes to blood-brain barrier leakage in transgenic human amyloid precursor protein mice and in humans with cerebral amyloid angiopathy Stroke 43 2012 514 523
80. C.A. Hawkes, P.M. Sullivan, S. Hands, R.O. Weller, J.A. Nicoll, and R.O. Carare Disruption of arterial perivascular drainage of amyloid-β from the brains of mice expressing the human APOE ε4 allele PLoS ONE 7 2012 e41636
81. D. Head, J.M. Bugg, A.M. Goate, A.M. Fagan, M.A. Mintun, T. Benzinger, D.M. Holtzman, and J.C. Morris Exercise Engagement as a Moderator of the Effects of APOE Genotype on Amyloid Deposition Arch. Neurol. 69 2012 636 643
82. C.C. Hedrick, S.R. Thorpe, M.X. Fu, C.M. Harper, J. Yoo, S.M. Kim, H. Wong, and A.L. Peters Glycation impairs high-density lipoprotein function Diabetologia 43 2000 312 320
83. J.W. Heinecke The HDL proteome: a marker - and perhaps mediator - of coronary artery disease J. Lipid Res. 50 Suppl 2009 S167 S171
84. E.P. Helzner, J.A. Luchsinger, N. Scarmeas, S. Cosentino, A.M. Brickman, M.M. Glymour, and Y. Stern Contribution of vascular risk factors to the progression in Alzheimer disease Arch. Neurol. 66 2009 343 348
85. K. Herholz Cerebral glucose metabolism in preclinical and prodromal Alzheimer's disease Expert Rev. Neurother. 10 2010 1667 1673
86. H. Hietanen, R. Pääkkönen, and V. Salomaa Ankle and exercise blood pressures as predictors of coronary morbidity and mortality in a prospective follow-up study J. Hum. Hypertens. 24 2010 577 584
87. H.J. Hietanen, R. Pääkkönen, and V. Salomaa Ankle blood pressure and pulse pressure as predictors of cerebrovascular morbidity and mortality in a prospective follow-up study Stroke Res. Treat. 2010 2011 729391
88. H. Hietanen, A. Pietilä, M. Kähönen, and V. Salomaa Ankle blood pressure and dementia: a prospective follow-up study Blood Press. Monit. 18 2013 16 20
89. V. Hirsch-Reinshagen, L.F. Maia, B.L. Burgess, J.F. Blain, K.E. Naus, S.A. McIsaac, P.F. Parkinson, J.Y. Chan, G.H. Tansley, and M.R. Hayden et al. The absence of ABCA1 decreases soluble ApoE levels but does not diminish amyloid deposition in two murine models of Alzheimer disease J. Biol. Chem. 280 2005 43243 43256
90. A. Hofman, A. Ott, M.M. Breteler, M.L. Bots, A.J. Slooter, F. van Harskamp, C.N. van Duijn, C. Van Broeckhoven, and D.E. Grobbee Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer's disease in the Rotterdam Study Lancet 349 1997 151 154
91. P. Hollingworth, D. Harold, R. Sims, A. Gerrish, J.C. Lambert, M.M. Carrasquillo, R. Abraham, M.L. Hamshere, J.S. Pahwa, V. Moskvina Alzheimer's Disease Neuroimaging Initiative CHARGE consortium EADI1 consortium Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease Nat. Genet. 43 2011 429 435
92. D.M. Holtzman, J. Herz, and G. Bu Apolipoprotein E and apolipoprotein E receptors: normal biology and roles in Alzheimer disease Cold Spring Harb Perspect Med 2 2012 a006312
93. E. Hudry, J. Dashkoff, A.D. Roe, S. Takeda, R.M. Koffie, T. Hashimoto, M. Scheel, T. Spires-Jones, M. Arbel-Ornath, and R. Betensky et al. Gene transfer of human Apoe isoforms results in differential modulation of amyloid deposition and neurotoxicity in mouse brain Sci. Transl. Med. 5 2013 ra161
94. C. Iadecola Neurovascular regulation in the normal brain and in Alzheimer's disease Nat. Rev. Neurosci. 5 2004 347 360
95. C. Iadecola, F. Zhang, K. Niwa, C. Eckman, S.K. Turner, E. Fischer, S. Younkin, D.R. Borchelt, K.K. Hsiao, and G.A. Carlson SOD1 rescues cerebral endothelial dysfunction in mice overexpressing amyloid precursor protein Nat. Neurosci. 2 1999 157 161
96. M.D. Ikonomovic, W.E. Klunk, E.E. Abrahamson, C.A. Mathis, J.C. Price, N.D. Tsopelas, B.J. Lopresti, S. Ziolko, W. Bi, and W.R. Paljug et al. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease Brain 131 2008 1630 1645
97. S.S. Im, and T.F. Osborne Liver x receptors in atherosclerosis and inflammation Circ. Res. 108 2011 996 1001
98. J.H. Ix, R. Katz, C.A. Peralta, I.H. de Boer, M.A. Allison, D.A. Bluemke, D.S. Siscovick, J.A. Lima, and M.H. Criqui A high ankle brachial index is associated with greater left ventricular mass MESA (Multi-Ethnic Study of Atherosclerosis) J. Am. Coll. Cardiol. 55 2010 342 349
99. W.J. Jagust, J.L. Eberling, B.R. Reed, C.A. Mathis, and T.F. Budinger Clinical studies of cerebral blood flow in Alzheimer's disease Ann. N Y Acad. Sci. 826 1997 254 262
100. W.J. Jagust, D. Bandy, K. Chen, N.L. Foster, S.M. Landau, C.A. Mathis, J.C. Price, E.M. Reiman, D. Skovronsky, R.A. Koeppe Alzheimer's Disease Neuroimaging Initiative The Alzheimer's Disease Neuroimaging Initiative positron emission tomography core Alzheimers Dement. 6 2010 221 229
101. W.J. Jagust, S.M. Landau Alzheimer's Disease Neuroimaging Initiative Apolipoprotein E, not fibrillar β-amyloid, reduces cerebral glucose metabolism in normal aging J. Neurosci. 32 2012 18227 18233
102. Q. Jiang, C.Y. Lee, S. Mandrekar, B. Wilkinson, P. Cramer, N. Zelcer, K. Mann, B. Lamb, T.M. Willson, and J.L. Collins et al. ApoE promotes the proteolytic degradation of Abeta Neuron 58 2008 681 693
103. K.A. Johnson, K. Jones, B.L. Holman, J.A. Becker, P.A. Spiers, A. Satlin, and M.S. Albert Preclinical prediction of Alzheimer's disease using SPECT Neurology 50 1998 1563 1571
104. K.A. Johnson, M. Gregas, J.A. Becker, C. Kinnecom, D.H. Salat, E.K. Moran, E.E. Smith, J. Rosand, D.M. Rentz, and W.E. Klunk et al. Imaging of amyloid burden and distribution in cerebral amyloid angiopathy Ann. Neurol. 62 2007 229 234
105. K.A. Johnson, N.C. Fox, R.A. Sperling, and W.E. Klunk Brain imaging in Alzheimer disease Cold Spring Harb Perspect Med 2 2012 a006213
106. S. Kalmijn, D. Foley, L. White, C.M. Burchfiel, J.D. Curb, H. Petrovitch, G.W. Ross, R.J. Havlik, and L.J. Launer Metabolic cardiovascular syndrome and risk of dementia in Japanese-American elderly men. The Honolulu-Asia aging study Arterioscler. Thromb. Vasc. Biol. 20 2000 2255 2260
107. C.M. Karch, A.T. Jeng, P. Nowotny, J. Cady, C. Cruchaga, and A.M. Goate Expression of novel Alzheimer's disease risk genes in control and Alzheimer's disease brains PLoS ONE 7 2012 e50976
108. A. Katz, C. Udata, E. Ott, L. Hickey, M.E. Burczynski, P. Burghart, O. Vesterqvist, and X. Meng Safety, pharmacokinetics, and pharmacodynamics of single doses of LXR-623, a novel liver X-receptor agonist, in healthy participants J. Clin. Pharmacol. 49 2009 643 649
109. M. Kawano, M. Kawakami, M. Otsuka, H. Yashima, T. Yaginuma, and A. Ueki Marked decrease of plasma apolipoprotein AI and AII in Japanese patients with late-onset non-familial Alzheimer's disease Clin. Chim. Acta 239 1995 209 211
110. S.M. Kim, M.J. Kim, H.Y. Rhee, C.W. Ryu, E.J. Kim, E.T. Petersen, and G.H. Jahng Regional cerebral perfusion in patients with Alzheimer's disease and mild cognitive impairment: effect of APOE epsilon4 allele Neuroradiology 55 2013 25 34
111. W.S. Kim, H. Li, K. Ruberu, S. Chan, D.A. Elliott, J.K. Low, D. Cheng, T. Karl, and B. Garner Deletion of Abca7 increases cerebral amyloid-β accumulation in the J20 mouse model of Alzheimer's disease J. Neurosci. 33 2013 4387 4394
112. M. Kivipelto, E.L. Helkala, M.P. Laakso, T. Hänninen, M. Hallikainen, K. Alhainen, H. Soininen, J. Tuomilehto, and A. Nissinen Midlife vascular risk factors and Alzheimer's disease in later life: longitudinal, population based study BMJ 322 2001 1447 1451
113. M. Kivipelto, E.L. Helkala, M.P. Laakso, T. Hänninen, M. Hallikainen, K. Alhainen, S. Iivonen, A. Mannermaa, J. Tuomilehto, A. Nissinen, and H. Soininen Apolipoprotein E epsilon4 allele, elevated midlife total cholesterol level, and high midlife systolic blood pressure are independent risk factors for late-life Alzheimer disease Ann. Intern. Med. 137 2002 149 155
114. M. Kivipelto, T. Ngandu, L. Fratiglioni, M. Viitanen, I. Kåreholt, B. Winblad, E.L. Helkala, J. Tuomilehto, H. Soininen, and A. Nissinen Obesity and vascular risk factors at midlife and the risk of dementia and Alzheimer disease Arch. Neurol. 62 2005 1556 1560
115. S. Koch, N. Donarski, K. Goetze, M. Kreckel, H.J. Stuerenburg, C. Buhmann, and U. Beisiegel Characterization of four lipoprotein classes in human cerebrospinal fluid J. Lipid Res. 42 2001 1143 1151
116. S. Kodama, S. Tanaka, K. Saito, M. Shu, Y. Sone, F. Onitake, E. Suzuki, H. Shimano, S. Yamamoto, and K. Kondo et al. Effect of aerobic exercise training on serum levels of high-density lipoprotein cholesterol: a meta-analysis Arch. Intern. Med. 167 2007 999 1008
117. R.P. Koldamova, I.M. Lefterov, M.I. Lefterova, and J.S. Lazo Apolipoprotein A-I directly interacts with amyloid precursor protein and inhibits A beta aggregation and toxicity Biochemistry 40 2001 3553 3560
118. R. Koldamova, M. Staufenbiel, and I. Lefterov Lack of ABCA1 considerably decreases brain ApoE level and increases amyloid deposition in APP23 mice J. Biol. Chem. 280 2005 43224 43235
119. A. Kontush, M. Lhomme, and M.J. Chapman Unraveling the complexities of the HDL lipidome J. Lipid Res. 54 2013 2950 2963
120. I. Kratzer, K. Wernig, U. Panzenboeck, E. Bernhart, H. Reicher, R. Wronski, M. Windisch, A. Hammer, E. Malle, A. Zimmer, and W. Sattler Apolipoprotein A-I coating of protamine-oligonucleotide nanoparticles increases particle uptake and transcytosis in an in vitro model of the blood-brain barrier J. Control. Release 117 2007 301 311
121. Y.M. Kuo, M.R. Emmerling, C.L. Bisgaier, A.D. Essenburg, H.C. Lampert, D. Drumm, and A.E. Roher Elevated low-density lipoprotein in Alzheimer's disease correlates with brain abeta 1-42 levels Biochem. Biophys. Res. Commun. 252 1998 711 715
122. M. Kuriyama, K. Takahashi, T. Yamano, Y. Hokezu, S. Togo, M. Osame, and T. Igakura Low levels of serum apolipoprotein A I and A II in senile dementia Jpn. J. Psychiatry Neurol. 48 1994 589 593
123. K.D. LaClair, K.F. Manaye, D.L. Lee, J.S. Allard, A.V. Savonenko, J.C. Troncoso, and P.C. Wong Treatment with bexarotene, a compound that increases apolipoprotein-E, provides no cognitive benefit in mutant APP/PS1 mice Mol. Neurodegener. 8 2013 18
124. M.J. LaDu, S.M. Gilligan, J.R. Lukens, V.G. Cabana, C.A. Reardon, L.J. Van Eldik, and D.M. Holtzman Nascent astrocyte particles differ from lipoproteins in CSF J. Neurochem. 70 1998 2070 2081
125. G.E. Landreth, P.E. Cramer, M.M. Lakner, J.R. Cirrito, D.W. Wesson, K.R. Brunden, and D.A. Wilson Response to comments on "ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models" Science 340 2013 924, g
126. D. Laurin, K.H. Masaki, L.R. White, and L.J. Launer Ankle-to-brachial index and dementia: the Honolulu-Asia Aging Study Circulation 116 2007 2269 2274
127. J.H. Lee, B.J. Bacskai, and C. Ayata Genetic animal models of cerebral vasculopathies Prog. Mol. Biol. Transl. Sci. 105 2012 25 55
128. I. Lefterov, N.F. Fitz, A.A. Cronican, A. Fogg, P. Lefterov, R. Kodali, R. Wetzel, and R. Koldamova Apolipoprotein A-I deficiency increases cerebral amyloid angiopathy and cognitive deficits in APP/PS1DeltaE9 mice J. Biol. Chem. 285 2010 36945 36957
129. G. Lesser, K. Kandiah, L.S. Libow, A. Likourezos, B. Breuer, D. Marin, R. Mohs, V. Haroutunian, and R. Neufeld Elevated serum total and LDL cholesterol in very old patients with Alzheimer's disease Dement. Geriatr. Cogn. Disord. 12 2001 138 145
130. G.T. Lesser, V. Haroutunian, D.P. Purohit, M. Schnaider Beeri, J. Schmeidler, L. Honkanen, R. Neufeld, and L.S. Libow Serum lipids are related to Alzheimer's pathology in nursing home residents Dement. Geriatr. Cogn. Disord. 27 2009 42 49
131. T.L. Lewis, D. Cao, H. Lu, R.A. Mans, Y.R. Su, L. Jungbauer, M.F. Linton, S. Fazio, M.J. LaDu, and L. Li Overexpression of human apolipoprotein A-I preserves cognitive function and attenuates neuroinflammation and cerebral amyloid angiopathy in a mouse model of Alzheimer disease J. Biol. Chem. 285 2010 36958 36968
132. Y. Li, J. Cam, and G. Bu Low-density lipoprotein receptor family: endocytosis and signal transduction Mol. Neurobiol. 23 2001 53 67
133. J. Lind, J. Persson, M. Ingvar, A. Larsson, M. Cruts, C. Van Broeckhoven, R. Adolfsson, L. Bäckman, L.G. Nilsson, K.M. Petersson, and L. Nyberg Reduced functional brain activity response in cognitively intact apolipoprotein E epsilon4 carriers Brain 129 2006 1240 1248
134. M.F. Linton, R. Gish, S.T. Hubl, E. Bütler, C. Esquivel, W.I. Bry, J.K. Boyles, M.R. Wardell, and S.G. Young Phenotypes of apolipoprotein B and apolipoprotein E after liver transplantation J. Clin. Invest. 88 1991 270 281
135. V. Llorente-Cortés, P. Costales, J. Bernués, S. Camino-Lopez, and L. Badimon Sterol regulatory element-binding protein-2 negatively regulates low density lipoprotein receptor-related protein transcription J. Mol. Biol. 359 2006 950 960
136. A. Lockhart, J.R. Lamb, T. Osredkar, L.I. Sue, J.N. Joyce, L. Ye, V. Libri, D. Leppert, and T.G. Beach PIB is a non-specific imaging marker of amyloid-beta (Abeta) peptide-related cerebral amyloidosis Brain 130 2007 2607 2615
137. W. Logge, D. Cheng, R. Chesworth, S. Bhatia, B. Garner, W.S. Kim, and T. Karl Role of Abca7 in mouse behaviours relevant to neurodegenerative diseases PLoS ONE 7 2012 e45959
138. J. Loren, Z. Huang, B.A. Laffitte, and V. Molteni Liver X receptor modulators: a review of recently patented compounds (2009 - 2012) Expert Opin Ther Pat 23 2013 1317 1335
139. S. Lund-Katz, and M.C. Phillips High density lipoprotein structure-function and role in reverse cholesterol transport Subcell. Biochem. 51 2010 183 227
140. S. Marco, and S.D. Skaper Amyloid beta-peptide1-42 alters tight junction protein distribution and expression in brain microvessel endothelial cells Neurosci. Lett. 401 2006 219 224
141. D. Masson, X.C. Jiang, L. Lagrost, and A.R. Tall The role of plasma lipid
142. C.L. Masters, and D.J. Selkoe Biochemistry of amyloid β-protein and amyloid deposits in Alzheimer disease Cold Spring Harb Perspect Med 2 2012 a006262
143. R. Mayeux, and Y. Stern Epidemiology of Alzheimer disease Cold Spring Harb Perspect Med 2 2012
144. M.O. McCarron, and J.A. Nicoll Apolipoprotein E genotype and cerebral amyloid angiopathy-related hemorrhage Ann. N Y Acad. Sci. 903 2000 176 179
145. B. McGuinness, and P. Passmore Can statins prevent or help treat Alzheimer's disease? J. Alzheimers Dis. 20 2010 925 933
146. A. Merched, Y. Xia, S. Visvikis, J.M. Serot, and G. Siest Decreased high-density lipoprotein cholesterol and serum apolipoprotein AI concentrations are highly correlated with the severity of Alzheimer's disease Neurobiol. Aging 21 2000 27 30
147. N. Methia, P. André, A. Hafezi-Moghadam, M. Economopoulos, K.L. Thomas, and D.D. Wagner ApoE deficiency compromises the blood brain barrier especially after injury Mol. Med. 7 2001 810 815
148. M.M. Mielke, P.B. Rosenberg, J. Tschanz, L. Cook, C. Corcoran, K.M. Hayden, M. Norton, P.V. Rabins, R.C. Green, and K.A. Welsh-Bohmer et al. Vascular factors predict rate of progression in Alzheimer disease Neurology 69 2007 1850 1858
149. M.M. Mielke, J.M. Leoutsakos, J.T. Tschanz, R.C. Green, Y. Tripodis, C.D. Corcoran, M.C. Norton, and C.G. Lyketsos Interaction between vascular factors and the APOE ε4 allele in predicting rate of progression in Alzheimer's disease J. Alzheimers Dis. 26 2011 127 134
150. C. Mineo, and P.W. Shaul Novel biological functions of high-density lipoprotein cholesterol Circ. Res. 111 2012 1079 1090
151. M. Miyata, and J.D. Smith Apolipoprotein E allele-specific antioxidant activity and effects on cytotoxicity by oxidative insults and beta-amyloid peptides Nat. Genet. 14 1996 55 61
152. K.S. Montine, C.N. Bassett, J.J. Ou, W.R. Markesbery, L.L. Swift, and T.J. Montine Apolipoprotein E allelic influence on human cerebrospinal fluid apolipoproteins J. Lipid Res. 39 1998 2443 2451
153. M.C. Morris, P.A. Scherr, L.E. Hebert, D.A. Bennett, R.S. Wilson, R.J. Glynn, and D.A. Evans The cross-sectional association between blood pressure and Alzheimer's disease in a biracial community population of older persons J. Gerontol. A Biol. Sci. Med. Sci. 55 2000 M130 M136
154. M.C. Morris, P.A. Scherr, L.E. Hebert, R.J. Glynn, D.A. Bennett, and D.A. Evans Association of incident Alzheimer disease and blood pressure measured from 13 years before to 2 years after diagnosis in a large community study Arch. Neurol. 58 2001 1640 1646
155. J.C. Morris, C.M. Roe, C. Xiong, A.M. Fagan, A.M. Goate, D.M. Holtzman, and M.A. Mintun APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging Ann. Neurol. 67 2010 122 131
156. M. Navab, S.S. Imes, S.Y. Hama, G.P. Hough, L.A. Ross, R.W. Bork, A.J. Valente, J.A. Berliner, D.C. Drinkwater, and H. Laks et al. Monocyte transmigration induced by modification of low density lipoprotein in cocultures of human aortic wall cells is due to induction of monocyte chemotactic protein 1 synthesis and is abolished by high density lipoprotein J. Clin. Invest. 88 1991 2039 2046
157. P.T. Nelson, N.M. Pious, G.A. Jicha, D.M. Wilcock, D.W. Fardo, S. Estus, and G.W. Rebeck APOE-ε2 and APOE-ε4 correlate with increased amyloid accumulation in cerebral vasculature J. Neuropathol. Exp. Neurol. 72 2013 708 715
158. A.B. Newman, A.L. Fitzpatrick, O. Lopez, S. Jackson, C. Lyketsos, W. Jagust, D. Ives, S.T. Dekosky, and L.H. Kuller Dementia and Alzheimer's disease incidence in relationship to cardiovascular disease in the Cardiovascular Health Study cohort J. Am. Geriatr. Soc. 53 2005 1101 1107
159. S.J. Nicholls, A. Gordon, J. Johannson, C.M. Ballantyne, P.J. Barter, H.B. Brewer, J.J. Kastelein, N.C. Wong, M.R. Borgman, and S.E. Nissen ApoA-I induction as a potential cardioprotective strategy: rationale for the SUSTAIN and ASSURE studies Cardiovasc. Drugs Ther. 26 2012 181 187
160. N. Nicolakakis, and E. Hamel Neurovascular function in Alzheimer's disease patients and experimental models J. Cereb. Blood Flow Metab. 31 2011 1354 1370
161. T. Ninomiya, T. Ohara, Y. Hirakawa, D. Yoshida, Y. Doi, J. Hata, S. Kanba, T. Iwaki, and Y. Kiyohara Midlife and late-life blood pressure and dementia in Japanese elderly: the Hisayama study Hypertension 58 2011 22 28
162. K. Nishitsuji, T. Hosono, T. Nakamura, G. Bu, and M. Michikawa Apolipoprotein E regulates the integrity of tight junctions in an isoform-dependent manner in an in vitro blood-brain barrier model J. Biol. Chem. 286 2011 17536 17542
163. S.E. Nissen, T. Tsunoda, E.M. Tuzcu, P. Schoenhagen, C.J. Cooper, M. Yasin, G.M. Eaton, M.A. Lauer, W.S. Sheldon, and C.L. Grines et al. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial JAMA 290 2003 2292 2300
164. K. Niwa, G.A. Carlson, and C. Iadecola Exogenous A beta1-40 reproduces cerebrovascular alterations resulting from amyloid precursor protein overexpression in mice J. Cereb. Blood Flow Metab. 20 2000 1659 1668
165. K. Niwa, L. Younkin, C. Ebeling, S.K. Turner, D. Westaway, S. Younkin, K.H. Ashe, G.A. Carlson, and C. Iadecola Abeta 1-40-related reduction in functional hyperemia in mouse neocortex during somatosensory activation Proc. Natl. Acad. Sci. USA 97 2000 9735 9740
166. E. Nobécourt, F. Tabet, G. Lambert, R. Puranik, S. Bao, L. Yan, M.J. Davies, B.E. Brown, A.J. Jenkins, and G.J. Dusting et al. Nonenzymatic glycation impairs the antiinflammatory properties of apolipoprotein A-I Arterioscler. Thromb. Vasc. Biol. 30 2010 766 772
167. J.R. Nofer, M. van der Giet, M. Tölle, I. Wolinska, K. von Wnuck Lipinski, H.A. Baba, U.J. Tietge, A. Gödecke, I. Ishii, and B. Kleuser et al. HDL induces NO-dependent vasorelaxation via the lysophospholipid receptor S1P3 J. Clin. Invest. 113 2004 569 581
168. I.L. Notkola, R. Sulkava, J. Pekkanen, T. Erkinjuntti, C. Ehnholm, P. Kivinen, J. Tuomilehto, and A. Nissinen Serum total cholesterol, apolipoprotein E epsilon 4 allele, and Alzheimer's disease Neuroepidemiology 17 1998 14 20
169. J.M. Olichney, L.A. Hansen, C.R. Hofstetter, J.H. Lee, R. Katzman, and L.J. Thal Association between severe cerebral amyloid angiopathy and cerebrovascular lesions in Alzheimer disease is not a spurious one attributable to apolipoprotein E4 Arch. Neurol. 57 2000 869 874
170. B. Pan, Y. Ma, H. Ren, Y. He, Y. Wang, X. Lv, D. Liu, L. Ji, B. Yu, and Y. Wang et al. Diabetic HDL is dysfunctional in stimulating endothelial cell migration and proliferation due to down regulation of SR-BI expression PLoS ONE 7 2012 e48530
171. L. Park, J. Zhou, P. Zhou, R. Pistick, S. El Jamal, L. Younkin, J. Pierce, A. Arreguin, J. Anrather, and S.G. Younkin et al. Innate immunity receptor CD36 promotes cerebral amyloid angiopathy Proc. Natl. Acad. Sci. USA 110 2013 3089 3094
172. P.J. Patel, A.V. Khera, K. Jafri, R.L. Wilensky, and D.J. Rader The anti-oxidative capacity of high-density lipoprotein is reduced in acute coronary syndrome but not in stable coronary artery disease J. Am. Coll. Cardiol. 58 2011 2068 2075
173. P.J. Patel, A.V. Khera, R.L. Wilensky, and D.J. Rader Anti-oxidative and cholesterol efflux capacities of high-density lipoprotein are reduced in ischaemic cardiomyopathy Eur. J. Heart Fail. 15 2013 1215 1219
174. A.C. Paula-Lima, M.A. Tricerri, J. Brito-Moreira, T.R. Bomfim, F.F. Oliveira, M.H. Magdesian, L.T. Grinberg, R. Panizzutti, and S.T. Ferreira Human apolipoprotein A-I binds amyloid-beta and prevents Abeta-induced neurotoxicity Int. J. Biochem. Cell Biol. 41 2009 1361 1370
175. R. Peters, and N. Beckett Hypertension, dementia, and antihypertensive treatment: implications for the very elderly Curr. Hypertens. Rep. 11 2009 277 282
176. R.E. Pitas, J.K. Boyles, S.H. Lee, D. Hui, and K.H. Weisgraber Lipoproteins and their receptors in the central nervous system. Characterization of the lipoproteins in cerebrospinal fluid and identification of apolipoprotein B,E(LDL) receptors in the brain J. Biol. Chem. 262 1987 14352 14360
177. K.H. Pitkälä, M.M. Pöysti, M.L. Laakkonen, R.S. Tilvis, N. Savikko, H. Kautiainen, and T.E. Strandberg Effects of the Finnish Alzheimer disease exercise trial (FINALEX): a randomized controlled trial JAMA Intern. Med. 173 2013 894 901
178. M.M. Poels, M. van Oijen, F.U. Mattace-Raso, A. Hofman, P.J. Koudstaal, J.C. Witteman, and M.M. Breteler Arterial stiffness, cognitive decline, and risk of dementia: the Rotterdam study Stroke 38 2007 888 892
179. D.R. Premkumar, D.L. Cohen, P. Hedera, R.P. Friedland, and R.N. Kalaria Apolipoprotein E-epsilon4 alleles in cerebral amyloid angiopathy and cerebrovascular pathology associated with Alzheimer's disease Am. J. Pathol. 148 1996 2083 2095
180. A.R. Price, G. Xu, Z.B. Siemienski, L.A. Smithson, D.R. Borchelt, T.E. Golde, and K.M. Felsenstein Comment on "ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models" Science 340 2013 924, d
181. M. Puchades, S.F. Hansson, C.L. Nilsson, N. Andreasen, K. Blennow, and P. Davidsson Proteomic studies of potential cerebrospinal fluid protein markers for Alzheimer's disease Brain Res. Mol. Brain Res. 118 2003 140 146
182. G.W. Rebeck, N.C. Alonzo, O. Berezovska, S.D. Harr, R.B. Knowles, J.H. Growdon, B.T. Hyman, and A.J. Mendez Structure and functions of human cerebrospinal fluid lipoproteins from individuals of different APOE genotypes Exp. Neurol. 149 1998 175 182
183. C. Reitz, M.X. Tang, N. Schupf, J.J. Manly, R. Mayeux, and J.A. Luchsinger Association of higher levels of high-density lipoprotein cholesterol in elderly individuals and lower risk of late-onset Alzheimer disease Arch. Neurol. 67 2010 1491 1497
184. C. Reitz, G. Jun, A. Naj, R. Rajbhandary, B.N. Vardarajan, L.S. Wang, O. Valladares, C.F. Lin, E.B. Larson, N.R. Graff-Radford Alzheimer Disease Genetics Consortium Variants in the ATP-binding cassette transporter (ABCA7), apolipoprotein E ε4,and the risk of late-onset Alzheimer disease in African Americans JAMA 309 2013 1483 1492
185. J.J. Repa, G. Liang, J. Ou, Y. Bashmakov, J.M. Lobaccaro, I. Shimomura, B. Shan, M.S. Brown, J.L. Goldstein, and D.J. Mangelsdorf Regulation of mouse sterol regulatory element-binding protein-1c gene (SREBP-1c) by oxysterol receptors, LXRalpha and LXRbeta Genes Dev. 14 2000 2819 2830
186. Resverlogix (2008). RVX-208 Exploratory Study Illustrates Early Potential for Alzheimer's Disease (http://www.resverlogix.com/upload/latest-news/81/01/ 2008-11-10-alzheimers-program-final.pdf).
187. Resverlogix (2011). Resverlogix ASSERT Trial Data Illustrates Potential for RVX-208 in Alzheimer's Disease (http://www.resverlogix.com/media/press- release.html?id=451).
188. Resverlogix (2013). Further Analysis of the ASSURE Data Finds a Responder Group for RVX-208 with Statistically Significant Regression of Coronary Atherosclerosis (http://www.resverlogix.com/media/press-release.html?id=492).
189. I.C. Ribeiro, R.T. Iborra, M.Q. Neves, S.A. Lottenberg, A.M. Charf, V.S. Nunes, C.E. Negrão, E.R. Nakandakare, E.C. Quintão, and M. Passarelli HDL atheroprotection by aerobic exercise training in type 2 diabetes mellitus Med. Sci. Sports Exerc. 40 2008 779 786
190. D.R. Riddell, H. Zhou, T.A. Comery, E. Kouranova, C.F. Lo, H.K. Warwick, R.H. Ring, Y. Kirksey, S. Aschmies, and J. Xu et al. The LXR agonist TO901317 selectively lowers hippocampal Abeta42 and improves memory in the Tg2576 mouse model of Alzheimer's disease Mol. Cell. Neurosci. 34 2007 621 628
191. M. Riwanto, and U. Landmesser High density lipoproteins and endothelial functions: mechanistic insights and alterations in cardiovascular disease J. Lipid Res. 54 2013 3227 3243
192. M. Riwanto, L. Rohrer, B. Roschitzki, C. Besler, P. Mocharla, M. Mueller, D. Perisa, K. Heinrich, L. Altwegg, and A. von Eckardstein et al. Altered activation of endothelial anti- and proapoptotic pathways by high-density lipoprotein from patients with coronary artery disease: role of high-density lipoprotein-proteome remodeling Circulation 127 2013 891 904
193. A.E. Roher, C.L. Maarouf, L.I. Sue, Y. Hu, J. Wilson, and T.G. Beach Proteomics-derived cerebrospinal fluid markers of autopsy-confirmed Alzheimer's disease Biomarkers 14 2009 493 501
194. G.A. Rosenberg Matrix metalloproteinases and their multiple roles in neurodegenerative diseases Lancet Neurol. 8 2009 205 216
195. C.C. Rowe, K.A. Ellis, M. Rimajova, P. Bourgeat, K.E. Pike, G. Jones, J. Fripp, H. Tochon-Danguy, L. Morandeau, and G. O'Keefe et al. Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging Neurobiol. Aging 31 2010 1275 1283
196. A. Ruitenberg, T. den Heijer, S.L. Bakker, J.C. van Swieten, P.J. Koudstaal, A. Hofman, and M.M. Breteler Cerebral hypoperfusion and clinical onset of dementia: the Rotterdam Study Ann. Neurol. 57 2005 789 794
197. S.M. Sacre, A.K. Stannard, and J.S. Owen Apolipoprotein E (apoE) isoforms differentially induce nitric oxide production in endothelial cells FEBS Lett. 540 2003 181 187
198. A.P. Sagare, R.D. Bell, and B.V. Zlokovic Neurovascular dysfunction and faulty amyloid β-peptide clearance in Alzheimer disease Cold Spring Harb Perspect Med 2 2012
199. T. Saido, and M.A. Leissring Proteolytic degradation of amyloid β-protein Cold Spring Harb Perspect Med 2 2012 a006379
200. K. Saito, M. Seishima, M.P. Heyes, H. Song, S. Fujigaki, S. Maeda, J.H. Vickers, and A. Noma Marked increases in concentrations of apolipoprotein in the cerebrospinal fluid of poliovirus-infected macaques: relations between apolipoprotein concentrations and severity of brain injury Biochem. J. 321 1997 145 149
201. K. Sattler, and B. Levkau Sphingosine-1-phosphate as a mediator of high-density lipoprotein effects in cardiovascular protection Cardiovasc. Res. 82 2009 201 211
202. D. Schley, R. Carare-Nnadi, C.P. Please, V.H. Perry, and R.O. Weller Mechanisms to explain the reverse perivascular transport of solutes out of the brain J. Theor. Biol. 238 2006 962 974
203. G.G. Schwartz, A.G. Olsson, M. Abt, C.M. Ballantyne, P.J. Barter, J. Brumm, B.R. Chaitman, I.M. Holme, D. Kallend, L.A. Leiter dal-OUTCOMES Investigators Effects of dalcetrapib in patients with a recent acute coronary syndrome N. Engl. J. Med. 367 2012 2089 2099
204. A.S. Shah, L. Tan, J.L. Long, and W.S. Davidson Proteomic diversity of high density lipoproteins: our emerging understanding of its importance in lipid transport and beyond J. Lipid Res. 54 2013 2575 2585
205. J.A. Shaw, A. Bobik, A. Murphy, P. Kanellakis, P. Blombery, N. Mukhamedova, K. Woollard, S. Lyon, D. Sviridov, and A.M. Dart Infusion of reconstituted high-density lipoprotein leads to acute changes in human atherosclerotic plaque Circ. Res. 103 2008 1084 1091
206. Y.I. Sheline, J.C. Morris, A.Z. Snyder, J.L. Price, Z. Yan, G. D'Angelo, C. Liu, S. Dixit, T. Benzinger, and A. Fagan et al. APOE4 allele disrupts resting state fMRI connectivity in the absence of amyloid plaques or decreased CSF Aβ42 J. Neurosci. 30 2010 17035 17040
207. N.E. Shepardson, G.M. Shankar, and D.J. Selkoe Cholesterol level and statin use in Alzheimer disease: I. Review of epidemiological and preclinical studies Arch. Neurol. 68 2011 1239 1244
208. N.E. Shepardson, G.M. Shankar, and D.J. Selkoe Cholesterol level and statin use in Alzheimer disease: II. Review of human trials and recommendations Arch. Neurol. 68 2011 1385 1392
209. J. Shin, S.Y. Lee, S.J. Kim, S.H. Kim, S.J. Cho, and Y.B. Kim Voxel-based analysis of Alzheimer's disease PET imaging using a triplet of radiotracers: PIB, FDDNP, and FDG Neuroimage 52 2010 488 496
210. C.R. Sirtori, L. Calabresi, G. Franceschini, D. Baldassarre, M. Amato, J. Johansson, M. Salvetti, C. Monteduro, R. Zulli, M.L. Muiesan, and E. Agabiti-Rosei Cardiovascular status of carriers of the apolipoprotein A-I(Milano) mutant: the Limone sul Garda study Circulation 103 2001 1949 1954
211. C.D. Smith, A.H. Andersen, R.J. Kryscio, F.A. Schmitt, M.S. Kindy, L.X. Blonder, and M.J. Avison Altered brain activation in cognitively intact individuals at high risk for Alzheimer's disease Neurology 53 1999 1391 1396
212. A. Solomon, M. Kivipelto, B. Wolozin, J. Zhou, and R.A. Whitmer Midlife serum cholesterol and increased risk of Alzheimer's and vascular dementia three decades later Dement. Geriatr. Cogn. Disord. 28 2009 75 80
213. H. Song, K. Saito, M. Seishima, A. Noma, K. Urakami, and K. Nakashima Cerebrospinal fluid apo E and apo A-I concentrations in early- and late-onset Alzheimer's disease Neurosci. Lett. 231 1997 175 178
214. H. Song, M. Seishima, K. Saito, S. Maeda, M. Takemura, A. Noma, A. Kondo, M. Manabe, K. Urakami, and K. Nakashima Apo A-I and apo E concentrations in cerebrospinal fluids of patients with acute meningitis Ann. Clin. Biochem. 35 1998 408 414
215. S.A. Sorrentino, C. Besler, L. Rohrer, M. Meyer, K. Heinrich, F.H. Bahlmann, M. Mueller, T. Horváth, C. Doerries, and M. Heinemann et al. Endothelial-vasoprotective effects of high-density lipoprotein are impaired in patients with type 2 diabetes mellitus but are improved after extended-release niacin therapy Circulation 121 2010 110 122
216. D.L. Sparks, S.W. Scheff, H. Liu, T.M. Landers, C.M. Coyne, and J.C. Hunsaker 3rd Increased incidence of neurofibrillary tangles (NFT) in non-demented individuals with hypertension J. Neurol. Sci. 131 1995 162 169
217. T. Speer, L. Rohrer, P. Blyszczuk, R. Shroff, K. Kuschnerus, N. Kränkel, G. Kania, S. Zewinger, A. Akhmedov, and Y. Shi et al. Abnormal high-density lipoprotein induces endothelial dysfunction via activation of Toll-like receptor-2 Immunity 38 2013 754 768
218. A.K. Stannard, D.R. Riddell, S.M. Sacre, A.D. Tagalakis, C. Langer, A. von Eckardstein, P. Cullen, T. Athanasopoulos, G. Dickson, and J.S. Owen Cell-derived apolipoprotein E (ApoE) particles inhibit vascular cell adhesion molecule-1 (VCAM-1) expression in human endothelial cells J. Biol. Chem. 276 2001 46011 46016
219. J.M. Starr, L.J. Whalley, S. Inch, and P.A. Shering Blood pressure and cognitive function in healthy old people J. Am. Geriatr. Soc. 41 1993 753 756
220. S. Stukas, S. May, A. Wilkinson, J. Chan, J. Donkin, and C.L. Wellington The LXR agonist GW3965 increases apoA-I protein levels in the central nervous system independent of ABCA1 Biochim. Biophys. Acta 1821 2012 536 546
221. L.M. Tai, K.A. Holloway, D.K. Male, A.J. Loughlin, and I.A. Romero Amyloid-beta-induced occludin down-regulation and increased permeability in human brain endothelial cells is mediated by MAPK activation J. Cell. Mol. Med. 14 2010 1101 1112
222. N. Tanaka, S. Abe-Dohmae, N. Iwamoto, and S. Yokoyama Roles of ATP-binding cassette transporter A7 in cholesterol homeostasis and host defense system J. Atheroscler. Thromb. 18 2011 274 281
223. J.C. Tardif, J. Grégoire, P.L. L'Allier, R. Ibrahim, J. Lespérance, T.M. Heinonen, S. Kouz, C. Berry, R. Basser, M.A. Lavoie Effect of rHDL on Atherosclerosis-Safety and Efficacy (ERASE) Investigators Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial JAMA 297 2007 1675 1682
224. T. Tarumi, J. Sugawara, and H. Tanaka Association between ankle blood pressure and central arterial wave reflection J. Hum. Hypertens. 25 2011 539 544
225. M.R. Taskinen Diabetic dyslipidaemia: from basic research to clinical practice Diabetologia 46 2003 733 749
226. N. Terasaka, S. Yu, L. Yvan-Charvet, N. Wang, N. Mzhavia, R. Langlois, T. Pagler, R. Li, C.L. Welch, I.J. Goldberg, and A.R. Tall ABCG1 and HDL protect against endothelial dysfunction in mice fed a high-cholesterol diet J. Clin. Invest. 118 2008 3701 3713
227. N. Terasaka, M. Westerterp, J. Koetsveld, C. Fernández-Hernando, L. Yvan-Charvet, N. Wang, W.C. Sessa, and A.R. Tall ATP-binding cassette transporter G1 and high-density lipoprotein promote endothelial NO synthesis through a decrease in the interaction of caveolin-1 and endothelial NO synthase Arterioscler. Thromb. Vasc. Biol. 30 2010 2219 2225
228. I. Tesseur, A.C. Lo, A. Roberfroid, S. Dietvorst, B. Van Broeck, M. Borgers, H. Gijsen, D. Moechars, M. Mercken, and J. Kemp et al. Comment on "ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models" Science 340 2013 924, e
229. Alzheimer's Disease Anti-inflammatory Prevention Trial Research Group Results of a follow-up study to the randomized Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT) Alzheimers Dement. 9 2013 714 723
230. T. Thomas, G. Thomas, C. McLendon, T. Sutton, and M. Mullan beta-Amyloid-mediated vasoactivity and vascular endothelial damage Nature 380 1996 168 171
231. J. Tian, J. Shi, K. Bailey, C.L. Lendon, S.M. Pickering-Brown, and D.M. Mann Association between apolipoprotein E e4 allele and arteriosclerosis, cerebral amyloid angiopathy, and cerebral white matter damage in Alzheimer's disease J. Neurol. Neurosurg. Psychiatry 75 2004 696 699
232. F. Torino, A. Barnabei, R. Paragliola, R. Baldelli, M. Appetecchia, and S.M. Corsello Thyroid dysfunction as an unintended side effect of anticancer drugs Thyroid 23 2013 1345 1366
233. K.P. Townsend, D. Obregon, A. Quadros, N. Patel, Ch. Volmar, D. Paris, and M. Mullan Proinflammatory and vasoactive effects of Abeta in the cerebrovasculature Ann. N Y Acad. Sci. 977 2002 65 76
234. J.D. Ulrich, J.M. Burchett, J.L. Restivo, D.R. Schuler, P.B. Verghese, T.E. Mahan, G.E. Landreth, J.M. Castellano, H. Jiang, J.R. Cirrito, and D.M. Holtzman In vivo measurement of apolipoprotein E from the brain interstitial fluid using microdialysis Mol. Neurodegener. 8 2013 13
235. A. Undurti, Y. Huang, J.A. Lupica, J.D. Smith, J.A. DiDonato, and S.L. Hazen Modification of high density lipoprotein by myeloperoxidase generates a pro-inflammatory particle J. Biol. Chem. 284 2009 30825 30835
236. N.T. Vagelatos, and G.D. Eslick Type 2 Diabetes as a Risk Factor for Alzheimer's Disease: The Confounders, Interactions, and Neuropathology Associated With This Relationship Epidemiol. Rev. 2013
237. A.H. van Beek, J.A. Claassen, M.G. Rikkert, and R.W. Jansen Cerebral autoregulation: an overview of current concepts and methodology with special focus on the elderly J. Cereb. Blood Flow Metab. 28 2008 1071 1085
238. B.J. Van Lenten, S.Y. Hama, F.C. de Beer, D.M. Stafforini, T.M. McIntyre, S.M. Prescott, B.N. La Du, A.M. Fogelman, and M. Navab Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures J. Clin. Invest. 96 1995 2758 2767
239. M. van Oijen, F.J. de Jong, J.C. Witteman, A. Hofman, P.J. Koudstaal, and M.M. Breteler Atherosclerosis and risk for dementia Ann. Neurol. 61 2007 403 410
240. P.M. Vanhoutte, H. Shimokawa, E.H. Tang, and M. Feletou Endothelial dysfunction and vascular disease Acta Physiol. (Oxf.) 196 2009 193 222
241. T. Vanmierlo, K. Rutten, J. Dederen, V.W. Bloks, L.C. van Vark-van der Zee, F. Kuipers, A. Kiliaan, A. Blokland, E.J. Sijbrands, and H. Steinbusch et al. Liver X receptor activation restores memory in aged AD mice without reducing amyloid Neurobiol. Aging 32 2011 1262 1272
242. J.B. Vasquez, D.W. Fardo, and S. Estus ABCA7 expression is associated with Alzheimer's disease polymorphism and disease status Neurosci. Lett. 556 2013 58 62
243. K. Veeraraghavalu, C. Zhang, S. Miller, J.K. Hefendehl, T.W. Rajapaksha, J. Ulrich, M. Jucker, D.M. Holtzman, R.E. Tanzi, R. Vassar, and S.S. Sisodia Comment on "ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models" Science 340 2013 924, f
244. P.B. Verghese, J.M. Castellano, K. Garai, Y. Wang, H. Jiang, A. Shah, G. Bu, C. Frieden, and D.M. Holtzman ApoE influences amyloid-β (Aβ) clearance despite minimal apoE/Aβ association in physiological conditions Proc. Natl. Acad. Sci. USA 110 2013 E1807 E1816
245. S.E. Wahrle, H. Jiang, M. Parsadanian, J. Kim, A. Li, A. Knoten, S. Jain, V. Hirsch-Reinshagen, C.L. Wellington, and K.R. Bales et al. Overexpression of ABCA1 reduces amyloid deposition in the PDAPP mouse model of Alzheimer disease J. Clin. Invest. 118 2008 671 682
246. R. Waksman, R. Torguson, K.M. Kent, A.D. Pichard, W.O. Suddath, L.F. Satler, B.D. Martin, T.J. Perlman, J.A. Maltais, and N.J. Weissman et al. A first-in-man, randomized, placebo-controlled study to evaluate the safety and feasibility of autologous delipidated high-density lipoprotein plasma infusions in patients with acute coronary syndrome J. Am. Coll. Cardiol. 55 2010 2727 2735
247. S.R. Waldstein, S.C. Rice, J.F. Thayer, S.S. Najjar, A. Scuteri, and A.B. Zonderman Pulse pressure and pulse wave velocity are related to cognitive decline in the Baltimore Longitudinal Study of Aging Hypertension 51 2008 99 104
248. N. Wang, D. Lan, M. Gerbod-Giannone, P. Linsel-Nitschke, A.W. Jehle, W. Chen, L.O. Martinez, and A.R. Tall ATP-binding cassette transporter A7 (ABCA7) binds apolipoprotein A-I and mediates cellular phospholipid but not cholesterol efflux J. Biol. Chem. 278 2003 42906 42912
249. R.O. Weller, M. Subash, S.D. Preston, I. Mazanti, and R.O. Carare Perivascular drainage of amyloid-beta peptides from the brain and its failure in cerebral amyloid angiopathy and Alzheimer's disease Brain Pathol. 18 2008 253 266
250. D.W. Wesson, A.H. Borkowski, G.E. Landreth, R.A. Nixon, E. Levy, and D.A. Wilson Sensory network dysfunction, behavioral impairments, and their reversibility in an Alzheimer's β-amyloidosis mouse model J. Neurosci. 31 2011 15962 15971
251. C.E. Wierenga, L.R. Clark, S.I. Dev, D.D. Shin, S.M. Jurick, R.A. Rissman, T.T. Liu, and M.W. Bondi Interaction of age and APOE genotype on cerebral blood flow at rest J. Alzheimers Dis. 34 2013 921 935
252. H.A. Wishart, A.J. Saykin, L.A. Rabin, R.B. Santulli, L.A. Flashman, S.J. Guerin, A.C. Mamourian, D.R. Belloni, C.H. Rhodes, and T.W. McAllister Increased brain activation during working memory in cognitively intact adults with the APOE epsilon4 allele Am. J. Psychiatry 163 2006 1603 1610
253. R.S. Wright Recent clinical trials evaluating benefit of drug therapy for modification of HDL cholesterol Curr. Opin. Cardiol. 28 2013 389 398
254. L. Yue, J.T. Bian, I. Grizelj, A. Cavka, S.A. Phillips, A. Makino, and T. Mazzone Apolipoprotein E enhances endothelial-NO production by modulating caveolin 1 interaction with endothelial NO synthase Hypertension 60 2012 1040 1046
255. I.S. Yuhanna, Y. Zhu, B.E. Cox, L.D. Hahner, S. Osborne-Lawrence, P. Lu, Y.L. Marcel, R.G. Anderson, M.E. Mendelsohn, H.H. Hobbs, and P.W. Shaul High-density lipoprotein binding to scavenger receptor-BI activates endothelial nitric oxide synthase Nat. Med. 7 2001 853 857
256. A.R. Zazulia Regulation of cerebral blood flow in untreated mild-to-moderate hypertension Am. J. Hypertens. 22 2009 344
257. A. Zensi, D. Begley, C. Pontikis, C. Legros, L. Mihoreanu, C. Büchel, and J. Kreuter Human serum albumin nanoparticles modified with apolipoprotein A-I cross the blood-brain barrier and enter the rodent brain J. Drug Target. 18 2010 842 848
258. L. Zheng, B. Nukuna, M.L. Brennan, M. Sun, M. Goormastic, M. Settle, D. Schmitt, X. Fu, L. Thomson, and P.L. Fox et al. Apolipoprotein A-I is a selective target for myeloperoxidase-catalyzed oxidation and functional impairment in subjects with cardiovascular disease J. Clin. Invest. 114 2004 529 541
259. B.D. Zipser, C.E. Johanson, L. Gonzalez, T.M. Berzin, R. Tavares, C.M. Hulette, M.P. Vitek, V. Hovanesian, and E.G. Stopa Microvascular injury and blood-brain barrier leakage in Alzheimer's disease Neurobiol. Aging 28 2007 977 986
260. B.V. Zlokovic Neurovascular mechanisms of Alzheimer's neurodegeneration Trends Neurosci. 28 2005 202 208
261. B.V. Zlokovic The blood-brain barrier in health and chronic neurodegenerative disorders Neuron 57 2008 178 201
262. B.V. Zlokovic Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders Nat. Rev. Neurosci. 12 2011 723 738
263. B.V. Zlokovic Cerebrovascular effects of apolipoprotein E: implications for Alzheimer disease JAMA Neurol. 70 2013 440 444
264. G. Zuliani, M. Cavalieri, M. Galvani, S. Volpato, A. Cherubini, S. Bandinelli, A.M. Corsi, F. Lauretani, J.M. Guralnik, R. Fellin, and L. Ferrucci Relationship between low levels of high-density lipoprotein cholesterol and dementia in the elderly. The InChianti study J. Gerontol. A Biol. Sci. Med. Sci. 65 2010 559 564